340B Drug Rebates: Old Debate Revived, But Shot Down

Monitor Mondays

A major drug company’s attempt to turn 340B drug pricing program discounts into rebates made big headlines in recent weeks. Maureen Testoni, president and CEO of 340B Health, will review how this potentially major upheaval came about, how 340B stakeholders responded, and how the drugmaker backed off after the federal government threatened it with massive penalties.
This debate is by no means over.
The idea of imposing rebates in 340B is not a new one, and the concept has come back into prominence recently amid the ongoing implementation of the Inflation Reduction Act, which will have important effects on 340B.
Other segments during the weekly Internet broadcast will include these instantly recognizable features:
• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.
• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.
• Legislative Update: Folana Houston, assistant general counsel for Zelis, will report on current healthcare legislation.
• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.

Chapters

1. 340B Drug Rebates: Old Debate Revived, But Shot Down (00:00:00)

2. Ronald Hirsch, MD (00:01:08)

3. Knicole Emanuel, Esq (00:05:19)

4. RACmontior Commercial (00:11:39)

5. David Glaser, Esq (00:12:41)

6. Folana Houston, MPA (00:17:15)

7. RACmontior Commercial (00:21:47)

8. Maureen Testoni, JD (00:22:43)

9. Closing (00:27:19)